Sanofi Accused Of Shorting Staff For Sales Of Cancer Drug

Law360, Washington (September 19, 2013, 1:26 PM EDT) -- Two former Sanofi-Aventis US LLC sales employees hit the pharmaceutical giant with a putative class action Tuesday, claiming the company backtracked on commission agreements stemming from sales of the cancer drug Zaltrap.

Lead plaintiffs Lisa Overton and Merribeth Bazzell claimed that Sanofi refused to fully compensate Zaltrap sales representatives months after they exceeded expectations, despite repeated reassurances that the company would not change its sales incentive program.

Sanofi allegedly established and explained the “Sanofi Incentive Compensation Plan Policy” for Zaltrap sales in late August 2012, just...
To view the full article, register now.